Such alterations intersect pathways implicated in endocrine biology and resistance (ERα crosstalk, AP-1/SP1/NF-κB interfaces, PI3K–AKT/MAPK signaling) [64], offering tumor-specific hypotheses in breast, ovarian, endometrial, and colorectal settings. Here, ESR1 is linked to neoplasm.